Treatment of macular edema secondary to central vein occlusion

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201011295270N1

Enrollment

Registered

2010-12-01

Start date

2010-10-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central vein occlusion. Other retinal vascular occlusions

Interventions

Intravitreal injections of 1.25 mg of bevacizumab every five weeks until OCT central macular thickness is bellow 250 microns up to a limit of 6 consecutive injections. After normalization of CMT, pati

No control.

Treatment - Drugs

No control

Eligibility

Sex/Gender

All

Age

50 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion crieria: Visual acuity equal or worse than 20/40 and equal or greater than 20/400; Minimum OCT central thickness of 250 microns Onset of central vein occlusion between three and 12 months. Visual acuity better than 20/40 on the other eye Exclusion criteria: neovascularization of the retina, optic disk, iris or angle. Uncontrolled glaucoma Intraocular surgery and/or injection of any medication in the past 3 months

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Change of visual acuity. Timepoint: 6 months. Method of measurement: ETDRS chart.	—

Secondary

Measure	Time frame
OCT (Optical Coherence Tomograpy) central macular thickness changes. Timepoint: 6 months. Method of measurement: Stratus OCT.	—

Countries

Brazil

Contacts

Public ContactJanaina CR de Souza

Hospital Oftalmologico de Sorocaba

janamedsouza@ig.com.br00551132127000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026